MarginsXMarginsX
Home › Markets › Health Care › VRXA

Veraxa Biotech AG (VRXA)

VRXA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.04
-5.86% on the day
Market cap
$147.8M
Micro cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerVRXA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO yearNot reported by the screener
SEC CIK0002079109
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
no XBRL financials
Share count, 1 year
No year-earlier count
Going-concern doubt
No
20-F filed June 16, 2026
Insider net buying, 12 months
$83K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Based on this a ssessment, management has concluded that the Company has sufficient liquidity to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company's ability to continue as a going concern. 28 Cash flows for the years ended Decembe"
20-F 2026-06-16
Cash and burnno XBRL financialsNone on EDGAR
Shares outstanding141,407,813 (2026-06-10).Cover page 2026-06-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrassi & Co., CPAs, P.C., Jericho, New York, United StatesPCAOB Form AP 2026-06-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $83K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-04
Latest annual report20-F2026-06-16
Latest quarterly / interim6-K2026-10-15

Source: SEC EDGAR submissions feed, 56 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+16.8%
1 month-7.5%
3 months-41.3%
Year to date-89.6%
1 year-89.4%
From 52-week high-95.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
VRXAWVeraxa Biotech AG Warrants$0.0227

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M
SIONSionna Therapeutics Inc.$3.12-6.31%$141.1M
ZNTLZentalis Pharmaceuticals Inc.$1.60-5.88%$157.2M
RNAAtrium Therapeutics Inc.$6.43-14.38%$138.7M
MGNXMacroGenics Inc.$2.17-1.36%$138.7M
BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$1.98-7.48%$158.9M
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier